Capricor Therapeutics's quarterly market cap
increased
from Sep. 2025 ($329.62 Mil) to Dec. 2025 ($1,655.73 Mil) and
increased
from Dec. 2025 ($1,655.73 Mil) to Mar. 2026 ($1,753.02 Mil).
Capricor Therapeutics's annual market cap
increased
from Dec. 2023 ($152.31 Mil) to Dec. 2024 ($629.03 Mil) and
increased
from Dec. 2024 ($629.03 Mil) to Dec. 2025 ($1,655.73 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Capricor Therapeutics's Enterprise Value for Today is $1,444.58 Mil.
Capricor Therapeutics (NAS:CAPR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Capricor Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Capricor Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics (CAPR) has a Market Cap of $1,708.40 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Capricor Therapeutics and its competitors. According to the industry distribution chart, Capricor Therapeutics ranks #196 out of 1430 companies in the Biotechnology industry, placing it in the top 13.7%.
Is Capricor Therapeutics' Market Cap too high?
Capricor Therapeutics' current Market Cap is $1,708.40 Mil. The Biotechnology industry median Market Cap is 117.26. Capricor Therapeutics' value of $1,708.40 Mil is 1356.9% above this industry median. Based on the distribution chart, Capricor Therapeutics ranks #196 out of 1430 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Market Cap compare to SNDX and SLS?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #196 out of 1430 companies for Market Cap. This places Capricor Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.26. Capricor Therapeutics' value of $1,708.40 Mil is 1356.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Capricor Therapeutics's current Market Cap of $1,708.40 Mil is 1356.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Capricor Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current Market Cap is $1,708.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $29.50 — trading 505.7% above its estimated fair value. The current Market Cap is $1,708.40 Mil and 1356.9% above the Biotechnology industry median of 117.26. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Market Cap is $1,708.40 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Capricor Therapeutics (CAPR) Overvalued in 2026?
Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued.
The current stock price of $29.50 is trading 505.7% above its estimated GF Value™ of $4.87.
GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.
Key valuation signals for CAPR:
Market Cap: $1,708.40 Mil
GF Value™: $4.87 vs. price of $29.50 (505.7% above fair value)
Industry Position: 1356.9% above the Biotechnology median (#196 of 1430)
No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score
Get the complete analysis for CAPR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
